

Zeitschrift: Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften = Bulletin de l'Académie suisse des sciences médicales = Bollettino dell' Accademia svizzera delle scienze mediche

Herausgeber: Schweizerische Akademie der Medizinischen Wissenschaften

Band: 25 (1969)

Artikel: Indications for therapy with progestational agents

Autor: Darragh, A.

DOI: <https://doi.org/10.5169/seals-307799>

Nutzungsbedingungen

Die ETH-Bibliothek ist die Anbieterin der digitalisierten Zeitschriften auf E-Periodica. Sie besitzt keine Urheberrechte an den Zeitschriften und ist nicht verantwortlich für deren Inhalte. Die Rechte liegen in der Regel bei den Herausgebern beziehungsweise den externen Rechteinhabern. Das Veröffentlichen von Bildern in Print- und Online-Publikationen sowie auf Social Media-Kanälen oder Webseiten ist nur mit vorheriger Genehmigung der Rechteinhaber erlaubt. [Mehr erfahren](#)

Conditions d'utilisation

L'ETH Library est le fournisseur des revues numérisées. Elle ne détient aucun droit d'auteur sur les revues et n'est pas responsable de leur contenu. En règle générale, les droits sont détenus par les éditeurs ou les détenteurs de droits externes. La reproduction d'images dans des publications imprimées ou en ligne ainsi que sur des canaux de médias sociaux ou des sites web n'est autorisée qu'avec l'accord préalable des détenteurs des droits. [En savoir plus](#)

Terms of use

The ETH Library is the provider of the digitised journals. It does not own any copyrights to the journals and is not responsible for their content. The rights usually lie with the publishers or the external rights holders. Publishing images in print and online publications, as well as on social media channels or websites, is only permitted with the prior consent of the rights holders. [Find out more](#)

Download PDF: 30.01.2026

ETH-Bibliothek Zürich, E-Periodica, <https://www.e-periodica.ch>

Indications for Therapy with Progestational Agents

A. DARRAGH

The post war explosion in the rate of discovery and release of new potent pharmacological agents for general prescription has written a new chapter into the medical text books, that of "Iatrogenic Disorders". I mention this before passing on to discuss the indications for therapy with progestagens to stress that the prudent physician must weigh in the balance the *need* for treatment and the risk of side-effects. While the issues can clearly be seen in the short-term use of potent drugs to deal with brief episodes in ill patients, it is more difficult to bring the issues into perspective when what is being contemplated is the long-term exposure of a well person to potentially noxious agents to achieve a socially desirable effect with or without justification on strict medical grounds.

In the main, the indication for the administration of a progestagen is the correction of disorders of function arising from a relative or absolute deficiency of progesterone. Typically, such a situation arises with the cessation of luteal function in the female menstrual cycle with which the following changes have been described as being coincident (Table I).

While these changes in biochemical and physical parameters must be regarded as physiological concomitants of the withdrawal of ovarian hor-

Table I
Changes after cessation of luteal function

1. Weight gain	11. Lowered circulating level of vitamin A
2. Retention of Na^+ and Cl^-	12. Low blood sugar
3. Vasoconstriction	13. Stimulation of the pancreas
4. Increased capillary fragility	14. Greater tolerance for lactose
5. Presence of circulating fibrinolysin	15. Creatinuria
6. Greater urinary excretion of gonadotrophins	16. Low alveolar CO_2 tension
7. Decreased circulating eosinophiles	17. Reduction in tissue and plasma monoamine oxidase
8. Decrease in platelets	18. Decreased sexual excitability
9. Increased release of adrenal formaldehydic steroids	19. Accelerated protein catabolism
10. Decreased serum diastase	20. Lower basal temperature

Table II
Clinical uses of progestogens

1. Amenorrhoeas	7. Contraception
2. Dysfunctional uterine bleeding	8. Mazoplasia and virginal breast hypertrophy
3. Essential dysmenorrhoea	9. Nymphomania
4. Endometriosis	10. Delay of menstruation
5. Premenstrual tension	11. Psychiatric disorders associated with progesterone withdrawal or imbalance
6. Adenomatous endometrial hyperplasia (carcinoma in situ)	12. Migraine

Table III
Six main criteria in selecting progestogen

1. Potency	4. Convenience
2. Specificity	5. Suitability to the subject
3. Safety	6. Economy

mones, both estrogens and progestagens, certain clinical entities have become recognised as attributable to pathophysiological reactions which can be corrected by the administration of a progestagen alone.

If I may be excused for indulging for a moment in semantics, the title of this present session of our seminar is open to double interpretation. "Indications for Therapy with Progestational Agents" can mean either the clinical and laboratory indices which point to the *need* for therapy with such compounds, an aspect which has been very well examined so far. To avoid repetition therefore, may I ascribe a second meaning to the title and suggest that it could also be taken to mean – "The Parameters by which the suitability of a progestational agent for use in therapeutics may be assessed."

If we look at the accepted and the possible or potential clinical applications for progestogens (Table II), one indication, contraception, above all others stands out as different and distinct for special consideration because the recipient of therapy will be, in most instances, a very normal and a very healthy young woman. Therefore, the choice of preparation to be administered to her over a possible protracted period of time requires a great deal more thought about its selection and suitability for the individual subject than appears to be the case in the vast majority of instances to-day.

Six main criteria should guide the physician in selecting the most suitable progestogen for a particular subject (Table III).

1. *Potency*

The relative potency of progesterone and progestational agents using the induction of withdrawal bleeding as an index can be seen from Table IV.

Table IV
Relative potency of progesterone and progestational agents

Agent	Dose (mg/day for 5 days)
Progesterone	90-100
Ethisterone	20- 30
Dydrogesterone	5- 10
Ro 4-8347	1- 4
Norethisterone	2.5-5
Medroxyprogesterone acetate	2.5-5
Ethinodiol diacetate	0.5-1

2. *Specificity*

It is clearly of importance that particularly when a substance is to be administered chronically that it should have precise and specific range of activity. The following table indicates the spill-over of hormonal effect associated with the principle progestational agents in common clinical use to-day and compares them with the activity of a new retrosteroid Ro 4-8347 (Table V).

3. *Safety*

With the exception of those progestogens which have a 17-alkyl substituent in their formulae, the progestational agents we are considering have so far in their pure form, been singularly free from toxic effect. The 17 substituted compounds share with methyltestosterone the risk of causing cholestatic jaundice.

4. *Convenience*

All of the preparations share the convenience of being effective in once daily oral dosage schedules.

5. *Suitability to the subject*

Obviously, it would be undesirable to add a further hormonal stimulus of the same character to a patient that already demonstrates clinical evidence of androgenic response or excess estrogenic response. For example, the patient with evidence of hirsutism with or without acne is liable to experience an exacerbation if treated with a progestogen which carries an androgenic overlay of hormonal activity.

The induction of monoamine oxidase by progesterone and certain progestogenic substances is associated with the occurrence of depression and loss of libido in some patients treated with progestational agents. Caution must therefore be exercised especially in patients with a known history of depression when the use of progestational steroids is contemplated.

Table V

Spill-over of hormonal effect associated with principal progestational agents in comparison with Ro 4-8347

	Proges- tational	Estro- genic	Andro- genic	Ana- bolic	Anti- estro- genic	Pregnancy main- tenance
Norethynodrel	+	—	0	0	0	0
Norethindrone	+	0	+	+	+	0
Medroxyprogesterone acetate	+	0	+	?	+	+
Chlormadinone acetate	+	0	?	?	+	+
Ethinodiol diacetate..	+	+	—	0	+	0
Ro 4-8347	+	0	0	0	0	+

+ = Androgenicity in female rabbit fetuses.

? = No information available.

Progestational agents have been found useful in the management of many clinical conditions. The potency, specificity, safety and convenience of Ro 4-8347, a new retrosteroid progestational compound, must be taken as indications which warrant making it more widely available for clinical use with a view to diminishing the incidence of iatrogenic disorders precipitated by the use of non-specific progestational agents.

Author's address: Dr. Austin Darragh, Psycho-Endocrine Centre (U. C. D.), St. Kevin's Hospital, Dublin (Eire).

Discussion

E. DICZFALUSY: I noticed that you did not include in your list the homosteroid norgestrel which seems to be for the time being perhaps the most active on a weight basis.

A. DARRAGH: I have not had an opportunity of studying it, so that I did not include that on it.